World's Best Scientists 2026 revealed!

D-Index & Metrics

Microbiology

D-Index
45
Citations
12930
World Ranking
4955
National Ranking
1920

Best Publications

  • Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection

    Jordan J. Feld;Ira M. Jacobson;Christophe Hézode;Tarik Asselah

  • Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection

    Graham R. Foster;Nezam Afdhal;Stuart K. Roberts;Norbert Bräu

  • Lopinavir–Ritonavir versus Nelfinavir for the Initial Treatment of HIV Infection

    Sharon Walmsley;Barry Bernstein;Martin King;José Arribas

  • Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials

    Bonaventura Clotet;Nicholas Bellos;Jean Michel Molina;David Cooper

  • Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1

    Susanna Naggie;Curtis Cooper;Michael Saag;Kimberly Workowski

  • Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1

    David L. Wyles;Peter J. Ruane;Mark S. Sulkowski;Douglas Dieterich

  • Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection

    Stefan Zeuzem;Graham R Foster;Stanley Wang;Armen Asatryan

  • Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.

    Kenneth H Mayer;Kenneth H Mayer;Jean-Michel Molina;Melanie A Thompson;Peter L Anderson

  • Antiviral Activity, Pharmacokinetics, and Dose Response of the HIV-1 Integrase Inhibitor GS-9137 (JTK-303) in Treatment-Naive and Treatment-Experienced Patients

    Edwin Dejesus;Daniel Berger;Martin Markowitz;Calvin Cohen

  • Clinical targeting of HIV capsid protein with a long-acting small molecule.

    John O. Link;Martin S. Rhee;Winston C. Tse;Jim Zheng

  • Ombitasvir, Paritaprevir Co-dosed With Ritonavir, Dasabuvir, and Ribavirin for Hepatitis C in Patients Co-infected With HIV-1: A Randomized Trial

    Mark S. Sulkowski;Joseph J. Eron;David Wyles;Roger Trinh

  • Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults.

    Peter J. Ruane;Edwin DeJesus;Daniel Berger;Martin Markowitz

  • Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study.

    Robert T Schooley;Peter Ruane;Robert A Myers;Gildon Beall

  • Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection.

    Unknown

  • Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials

    Ira M. Jacobson;Ira M. Jacobson;Eric Lawitz;Edward J. Gane;Bernard E. Willems

  • Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19

    Unknown

  • HIV-1 Protease Mutations and Protease Inhibitor Cross-Resistance

    Soo-Yon Rhee;Jonathan Taylor;W. Jeffrey Fessel;David Kaufman

  • Risk Factors for Community-Associated Methicillin-Resistant Staphylococcus aureus Skin Infections among HIV-Positive Men Who Have Sex with Men

    Unknown

  • Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial

    Joel E Gallant;Eric S Daar;François Raffi;Cynthia Brinson

  • Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.

    Jean-Michel Molina;Douglas Ward;Indira Brar;Anthony Mills

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: